Search for drugs:
Typing the drug name to query
LUSUTROMBOPAG
DIR Classification
Classification:Ambiguous
Severity Score:1.0
Description in Drug Labeling: View Full Labeling: SPL in DailyMed | PDF
- CLINICAL PHARMACOLOGY
- Pharmacodynamics
- Cardiac Electrophysiology
- At a dose 8 times the recommended dosage, MULPLETA does not prolong QT interval to any clinically relevant extent.
Postmarketing Surveillance
Contingency Table:
Current Drug
Other Drugs
QT Prolongation
0
24092
Other ADRs
0
38381587
Odds Ratio = N/A
Drug Property Information
ATC Code(s):
- B02BX07 - lusutrombopag
- B02BX0 -
- B02BX - Other systemic hemostatics
- B02B - VITAMIN K AND OTHER HEMOSTATICS
- B02 - ANTIHEMORRHAGICS
- B - BLOOD AND BLOOD FORMING ORGANS
Active Ingredient:LUSUTROMBOPAG
Active Ingredient UNII:6LL5JFU42F
Drugbank ID:DB13125
PubChem Compound:49843517
CTD ID:C000611387
CAS Number:1110766-97-6
Dosage Form(s):tablet, film coated
Route(s) Of Administrator:oral
Daily Dose:
Chemical Structure: 
SMILE Code:
CCCCCCO[C@@H](C)C1=C(OC)C(=CC=C1)C1=CSC(NC(=O)C2=CC(Cl)=C(\C=C(/C)C(O)=O)C(Cl)=C2)=N1
CCCCCCO[C@@H](C)C1=C(OC)C(=CC=C1)C1=CSC(NC(=O)C2=CC(Cl)=C(\C=C(/C)C(O)=O)C(Cl)=C2)=N1
Reference
N/A
Disclaimer:
The content of this database of QT prolongation is intended for educational and scientific research purposes only. It is not intended as a substitute for professional medical advice, diagnosis or treatment.
Any mention of commercial products is for clarification and not intended as endorsement.